The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...
The FDA has approved Hyrnuo for some with locally advanced or metastatic non-squamous non–small cell lung cancer with ...
MedPage Today on MSN
New FDA-Approved Option for HER2-Mutated Lung Cancer
The FDA announced accelerated approval of sevabertinib (Hyrnuo) for HER2-positive non-small cell lung cancer (NSCLC).
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing ...
The small interfering RNA (siRNA) therapy, designed to reduce triglyceride levels by suppressing production of apolipoprotein ...
Plozasiran is the first FDA-approved drug for familial chylomicronemia syndrome, reducing triglycerides as an adjunct to diet ...
The ANDROMEDA trial showed improved MOD-PFS and OS with daratumumab and hyaluronidase plus VCd compared to VCd alone in light ...
The FDA has granted an accelerated approval to sevabertinib (Hyrnuo) for the treatment of adult patients with previously treated locally advanced or metastatic, nonsquamous non–small cell lung cancer ...
Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based ...
The top-line data from the first cohort demonstrate a favorable safety profile, with no serious adverse events reported and the treatment generally well-tolerated across all participants. Additionally ...
The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.
The U.S. Food and Drug Administration on Wednesday said it has approved Bayer's drug for patients with a type of lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback